Clinical-stage biopharmaceutical company developing CAR-T cell therapies for cancer treatment, with lead product cilta-cel for multiple myeloma.
Legend Biotech is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for oncology and other serious diseases. The company specializes in chimeric antigen receptor T-cell (CAR-T) therapies, with its lead product candidate ciltacabtagene autoleucel (cilta-cel) developed for multiple myeloma treatment. Founded with roots in China and later expanding globally, Legend Biotech has established a significant presence in the United States.
The company went public on NASDAQ in 2020 and has formed strategic partnerships with major pharmaceutical companies including Johnson & Johnson's Janssen unit for the development and commercialization of cilta-cel. Legend Biotech represents part of the growing cell and gene therapy sector, which has attracted substantial investment as these treatments show promise for treating previously intractable cancers and genetic diseases.
Legend Biotech has received investment from 1 venture capital firm.
Clinical-stage biopharmaceutical company developing CAR-T cell therapies for cancer treatment, with lead product cilta-cel for multiple myeloma.
Legend Biotech has received investment from Johnson & Johnson Innovation - JJDC. These venture capital firms and investors provide both capital and strategic support.
Legend Biotech operates in the Biotech sector. Clinical-stage biopharmaceutical company developing CAR-T cell therapies for cancer treatment, with lead product cilta-cel for multiple myeloma.
